Krakow B, Melendrez D, Ferreira E, et al., authors. Prevalence of insomnia symptoms in patients with sleep-disordered breathing. Chest. 2001;120:1923–9. [PubMed]
Smith S, Sullivan K, Hopkins W, Douglas J, authors. Frequency of insomnia report in patients with obstructive sleep apnoea hypopnea syndrome (OSAHS). Sleep Med. 2004;5:449–56. [PubMed]
Shepertycky MR, Banno K, Kryger MH, authors. Differences between men and women in the clinical presentation of patients diagnosed with obstructive sleep apnea syndrome. Sleep. 2005;28:309–14. [PubMed]
Guilleminault C, author. Benzodiazepines, breathing, and sleep. Am J Med. 1990;88:25S–28S.
Berry RB, Kouchi KG, Bower JL, Light RW, authors. Effect of upper airway anesthesia on obstructive sleep apnea. Am J Respir Crit Care Med. 1995;151:1857–61. [PubMed]
George CF, author. Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep. 2000;23 Suppl 1:S31–5. [PubMed]
Rosenberg R, Roach JM, Scharf M, Amato DA, authors. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med. 2007;8:464–70. [PubMed]
Eckert DJ, Owens RL, Kehlmann GB, et al., authors. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond). 2011;120:505–14. [PubMed]
Kilduff TS, Peyron C, authors. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000;23:359–65. [PubMed]
Brisbare-Roch C, Dingemanse J, Koberstein R, et al., authors. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13:150–5. [PubMed]
Sakurai T, author. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8:171–81. [PubMed]
Baumann CR, Bassetti CL, authors. Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol. 2005;4:673–82. [PubMed]
Scammell TE, Winrow CJ, authors. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243–66. [PubMed Central][PubMed]
Mieda M, Sakurai T, authors. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status. CNS Drugs. 2013;27:83–90. [PubMed]
Peyron C, Tighe DK, van den Pol AN, et al., authors. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996–10015. [PubMed]
Kuwaki T, author. Orexinergic modulation of breathing across vigilance states. Respir Physiol Neurobiol. 2008;164:204–12. [PubMed]
Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T, authors. Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol. 2007;103:1772–9. [PubMed]
Li A, Nattie E, authors. Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol. 2010;588:2935–44. [PubMed Central][PubMed]
Han F, Mignot E, Wei YC, et al., authors. Ventilatory chemoresponsiveness, narcolepsycataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J. 2010;36:577–83. [PubMed]
Cox CD, Breslin MJ, Whitman DB, et al., authors. Discovery of the dual orexin receptor antagonist[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320–32. [PubMed]
Winrow CJ, Gotter AL, Cox CD, et al., authors. Promotion of sleep by MK-4305 - a novel dual orexin receptor antagonist. J Neurogenetics. 2011;25:52–61. [PubMed]
Sun H, Kennedy WP, Wilbraham D, et al., authors. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36:259–67. [PubMed Central][PubMed]
Herring WJ, Snyder E, Budd K, et al., authors. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265–74. [PubMed]
Michelson D, Snyder E, Paradis E, et al., authors. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461–71. [PubMed]
Herring WJ, Connor KM, Ivgy-May N, et al., authors. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2014 Oct. 23. [Epub ahead of print].
Merck & Co. Inc. FDA approves BELSOMRA (suvorexant) for the treatment of insomnia. Press release, Aug 13, 2014. Accessed October 17, 2014. http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-belsomrasuvorexant-treatment-insomnia.
Sun H, Palcza J, Rosenberg R, et al., authors. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109:416–26. [PubMed]
American Academy of Sleep Medicine. International classification of sleep disorders, revised: Diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine, 2001.
Iber C, Ancoli-Israel S, Chesson AL, Quan SF, authors. The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specifications, 1st ed. Westchester, IL: American Academy of Sleep Medicine, 2007.
Rechtschaffen A, Kales A, authors. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington DC: National Institute of Health, Publication 204. Government Printing Office, 1968.
Rey A, author. L'examen clinique en psychologie. Paris, France: Presses Universitaires de France, 1964.
Wechsler D, author. WAIS-R manual. New York, NY: The Psychological Corporation, 1981.
Bond A, Lader M, authors. The use of analogue scales in rating subjective feelings. Br J Psychol. 1974;47:211–8.
Norris V, Baisley K, Calder N, van Troostenburg AR, Warrington S, authors. Assessment of the AccuSwayPLUS system in measuring the effect of lorazepam on body sway in healthy volunteers. Int J Pharm Med. 2005;19:233–8.
Kyrger M, Wang-Weigand S, Roth T, authors. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath. 2007;11:159–64. [PubMed]
Peppard PE, Young T, Palta M, Skatrud J, authors. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378–84. [PubMed]
Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE, authors. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol. 2004;160:521–30. [PubMed]
Bliwise DL, Benkert RE, Ingham RH, authors. Factors associated with nightly variability in sleep disordered breathing in the elderly. Chest. 1991;100:973–6. [PubMed]
Chediak AD, Acevedo-Crespo JC, Seiden DJ, Kim HH, Kiel MH, authors. Sleep disordered breathing: nightly variability in the indices of sleep-disordered breathing in men being evaluated for impotence with consecutive night polysomnograms. Sleep. 1996;19:589–92. [PubMed]
Uemura N, McCrea J, Sun H, et al., authors. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol. 2015;55:1093–100. [PubMed]
Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P, authors. Gender related differences in symptoms of patients with suspected breathing disorders in sleep: a clinical population study using the Sleep Disorders Questionnaire. Sleep. 2007;30:312–9. [PubMed]